National Comprehensive Cancer Network

NCCN Oncology Research Program Awards Grants for Innovative Prostate Cancer Research Involving Relugolix

PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has recently announced the awarding of grants for the development of innovative investigator-initiated research centered around …

NCCN Oncology Research Program Awards Grants for Innovative Prostate Cancer Research Involving Relugolix Read More

ZERO Philly Race

Philadelphia Joins the Fight Against Prostate Cancer: Local Event to Raise Funds and Awareness for Patients

PHILADELPHIA, PA — ZERO Prostate Cancer announced the return of its annual celebration of prostate cancer patients, survivors, caregivers, and families with its national Run/Walk series. ZERO joins MidLantic Urology …

Philadelphia Joins the Fight Against Prostate Cancer: Local Event to Raise Funds and Awareness for Patients Read More

Janssen Pharmaceutical

FDA Approval: AKEEGA, the Game-Changing Dual Action Tablet for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer Treatment

HORSHAM, PA — The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food & Drug Administration (FDA) recently approved AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action …

FDA Approval: AKEEGA, the Game-Changing Dual Action Tablet for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer Treatment Read More